PAVmed 8-K: Series Z Warrants Event Reported Jan 26

TL;DR

**PAVmed filed an 8-K about Series Z Warrants, watch for potential dilution.**

AI Summary

PAVmed Inc. filed an 8-K on January 30, 2024, reporting an event on January 26, 2024, related to its Series Z Warrants to Purchase Common Stock. This filing indicates an ongoing process or change concerning these specific warrants, which could impact the company's capital structure and potentially dilute existing shareholders if the warrants are exercised. Investors should monitor further details regarding these warrants as they could affect the stock's value.

Why It Matters

This filing signals an event related to PAVmed's Series Z Warrants, which could lead to dilution if exercised, impacting the value of existing common stock.

Risk Assessment

Risk Level: medium — The filing mentions an event related to warrants, which can introduce dilution risk for current shareholders if exercised.

Analyst Insight

Investors should seek further details regarding the nature of the event concerning the Series Z Warrants to understand potential impacts on share count and valuation.

Key Players & Entities

• PAVmed Inc. (company) — the registrant filing the 8-K
• Series Z Warrants to Purchase Common Stock (other) — the specific financial instrument mentioned in the filing
• January 26, 2024 (date) — date of the earliest event reported
• January 30, 2024 (date) — date the 8-K was filed

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, Par Value $0.001 Per Share PAVM The Nasdaq Stock Mar
• $4,675,256 — ompany ") elected to receive payment of $4,675,256 of fees and reimbursements due from Luc

Filing Documents

• form8-k.htm (8-K) — 42KB
• 0001493152-24-004350.txt ( ) — 253KB
• pavm-20240126.xsd (EX-101.SCH) — 4KB
• pavm-20240126_def.xml (EX-101.DEF) — 26KB
• pavm-20240126_lab.xml (EX-101.LAB) — 36KB
• pavm-20240126_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 5KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 26, 2024 PAVMED INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37685 47-1214177 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 360 Madison Avenue , 25 th Floor , New York , New York 10017 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (917) 813-1828 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.001 Per Share PAVM The Nasdaq Stock Market LLC Series Z Warrants to Purchase Common Stock PAVMZ The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01. Other Events. On January 26, 2024, PAVmed Inc. (the " Company ") elected to receive payment of $4,675,256 of fees and reimbursements due from Lucid Diagnostics Inc. (" Lucid Diagnostics "), the Company's majority owned subsidiary, through the issuance to the Company of 3,331,771 shares of Lucid Diagnostics' common stock. The transactions are described in more detail in the Current Report on Form 8-K filed by Lucid Diagnostics on January 30, 2024, which description is incorporated herein by reference. Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 30, 2024 PAVMED INC. By: /s/ Dennis M. McGrath Dennis M. McGrath President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR